Targeted protein degradation (TPD) has moved from promising concept to near-commercial reality in under a decade. By hijacking the cell’s
Continue Reading Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy – March 2026 Update
Background
Artificial Intelligence (“AI”) has been utilized by innovative companies across the array of industry spaces, but its impact on
Continue Reading Key IP Licensing Considerations for AI Drug Discovery Platforms
Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural
Continue Reading Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy
In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact
Continue Reading Key Patent Considerations for Antibody Drug Conjugates (ADCs)
The Unted States Patent and Trademark Office (USPTO) recently published new guidance on subject-matter eligibility as related to Artificial Intelligence
Continue Reading This Summer in Artificial Intelligence: Newly Released USPTO Guidance and Exemplary Worldwide Inventorship Updates